This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acquired pneumonia | 1326 |
respiratory tract | 555 |
bacterial pneumonia | 349 |
associated pneumonia | 344 |
pneumococcal pneumonia | 342 |
lower respiratory | 329 |
risk factors | 313 |
acute respiratory | 296 |
viral pneumonia | 285 |
streptococcus pneumoniae | 274 |
infectious diseases | 255 |
intensive care | 245 |
severe pneumonia | 239 |
antibiotic therapy | 213 |
respiratory syncytial | 205 |
syncytial virus | 198 |
intravenous drip | 198 |
united states | 191 |
aspiration pneumonia | 185 |
mechanical ventilation | 179 |
respiratory distress | 177 |
chest radiograph | 177 |
mg kg | 176 |
influenza virus | 175 |
mycoplasma pneumoniae | 166 |
staphylococcus aureus | 163 |
lung disease | 150 |
pleural effusion | 148 |
systematic review | 148 |
respiratory failure | 145 |
care unit | 143 |
tract infections | 142 |
cystic fibrosis | 141 |
chest radiographs | 140 |
community acquired | 137 |
severe cap | 132 |
viral infections | 132 |
respiratory viruses | 131 |
communityacquired pneumonia | 128 |
hospitalized patients | 127 |
antimicrobial drugs | 127 |
respiratory infections | 127 |
antimicrobial therapy | 124 |
severe community | 123 |
respiratory syndrome | 121 |
pulmonary disease | 121 |
interstitial pneumonia | 119 |
childhood pneumonia | 118 |
severe acute | 112 |
virus infection | 112 |
urinary antigen | 111 |
bronchoalveolar lavage | 109 |
thoracic society | 108 |
antibiotic treatment | 107 |
pneumococcal conjugate | 106 |
polymerase chain | 105 |
bacterial infections | 105 |
tract infection | 105 |
alveolar macrophages | 104 |
controlled trial | 104 |
diseases society | 104 |
clinical features | 103 |
chain reaction | 102 |
distress syndrome | 102 |
respiratory disease | 102 |
pneumococcal disease | 101 |
secondary bacterial | 100 |
combination therapy | 99 |
pseudomonas aeruginosa | 98 |
bacterial infection | 98 |
invasive pneumococcal | 97 |
elderly patients | 96 |
may occur | 95 |
lymph nodes | 95 |
haemophilus influenzae | 94 |
upper respiratory | 93 |
may also | 93 |
viral infection | 92 |
blood cultures | 92 |
causative microorganisms | 91 |
epithelial cells | 91 |
doc id | 90 |
bal fluid | 90 |
young children | 90 |
cord uid | 90 |
antimicrobial drug | 87 |
differential diagnosis | 86 |
pneumonia caused | 84 |
prospective study | 83 |
clinical practice | 83 |
hospital admission | 83 |
atypical pneumonia | 83 |
blood culture | 83 |
pneumonia patients | 82 |
mortality rate | 81 |
heart failure | 81 |
respiratory infection | 80 |
septic shock | 80 |
ill patients | 80 |
immunocompromised patients | 80 |
lung abscess | 80 |
chest radiography | 80 |
among patients | 80 |
health care | 80 |
human metapneumovirus | 79 |
patients hospitalized | 78 |
children aged | 78 |
pneumonia cases | 78 |
adult patients | 78 |
among children | 78 |
human beings | 77 |
clinical signs | 77 |
pleural effusions | 77 |
resistant bacteria | 76 |
pulmonary edema | 76 |
infectious disease | 76 |
critically ill | 75 |
parainfluenza virus | 75 |
conjugate vaccine | 74 |
world health | 74 |
chronic obstructive | 73 |
gram stain | 73 |
patients admitted | 71 |
bacterial pathogens | 71 |
increased risk | 70 |
reactive protein | 69 |
pulmonary infections | 69 |
pneumonia among | 68 |
icu admission | 68 |
pleural fluid | 68 |
health organization | 67 |
pulmonary infection | 67 |
herpes simplex | 67 |
immune response | 66 |
developing countries | 66 |
avian influenza | 66 |
pneumonia requiring | 65 |
severe cases | 64 |
bacteremic pneumococcal | 64 |
randomized controlled | 64 |
type i | 63 |
pneumonia may | 63 |
transplant recipients | 63 |
lung parenchyma | 63 |
chest ct | 62 |
lung injury | 62 |
common cause | 62 |
diagnostic tests | 62 |
obstructive pulmonary | 62 |
ct scan | 61 |
bone marrow | 61 |
type ii | 61 |
virus infections | 61 |
fl uid | 61 |
white blood | 61 |
atypical pathogens | 61 |
public health | 61 |
american thoracic | 60 |
respiratory pathogens | 60 |
pneumonia severity | 59 |
nosocomial pneumonia | 59 |
inflammatory response | 59 |
diagnostic testing | 58 |
severe disease | 58 |
cap patients | 58 |
foreign body | 57 |
legionella pneumophila | 57 |
respiratory symptoms | 57 |
study group | 57 |
practice guidelines | 56 |
ct findings | 56 |
lobar pneumonia | 56 |
respiratory rate | 56 |
patients without | 56 |
aged years | 56 |
clinical presentation | 55 |
antibiotic resistance | 55 |
infl uenza | 55 |
influenza pneumonia | 54 |
defense mechanisms | 54 |
mortality rates | 54 |
computed tomography | 53 |
chest pain | 53 |
high risk | 53 |
pneumonia etiology | 53 |
age group | 53 |
income countries | 53 |
may cause | 53 |
mg twice | 53 |
chlamydia pneumoniae | 52 |
virus pneumonia | 52 |
kg times | 52 |
cohort study | 51 |
severe sepsis | 51 |
many cases | 51 |
respiratory illness | 50 |
one study | 50 |
lower lobes | 49 |
disease control | 49 |
requiring hospitalization | 49 |
clinical characteristics | 48 |
emergency department | 48 |
hospital stay | 48 |
les patients | 48 |
nasal cavity | 48 |
related pneumonia | 47 |
giant cells | 47 |
clinical management | 47 |
physical examination | 47 |
mycoplasma pneumonia | 47 |
bronchiolitis obliterans | 47 |
simplex virus | 47 |
pneumonia incidence | 46 |
pneumonia due | 46 |
hiv infection | 46 |
see chapter | 46 |
underlying disease | 46 |
nursing home | 45 |
severely ill | 45 |
pediatric patients | 45 |
primary care | 45 |
blood cell | 45 |
influenza infection | 45 |
antigen test | 44 |
radiographic findings | 44 |
nucleic acid | 44 |
resistant staphylococcus | 44 |
ii pneumonocytes | 44 |
igg als | 44 |
leading cause | 44 |
blood pressure | 44 |
randomized trial | 44 |
antiviral therapy | 44 |
clinical trial | 43 |
upper lobe | 43 |
respiratory infectious | 43 |
observational study | 43 |
cell count | 43 |
molecular testing | 43 |
culture results | 43 |
oral therapy | 43 |
less common | 43 |
children younger | 43 |
respiratory system | 43 |
hospitalized children | 43 |
chronic respiratory | 43 |
mycobacterium tuberculosis | 42 |
sputum samples | 42 |
lung diseases | 42 |
multiplex pcr | 42 |
years old | 42 |
empiric therapy | 42 |
valent pneumococcal | 42 |
lower lobe | 42 |
ray images | 42 |
varicella pneumonia | 41 |
infection control | 41 |
lung biopsy | 41 |
hong kong | 41 |
organizing pneumonia | 41 |
le diagnostic | 41 |
escherichia coli | 41 |
risk factor | 41 |
acute lung | 41 |
clinical symptoms | 41 |
antimicrobial resistance | 41 |
diffuse alveolar | 41 |
among adults | 41 |
older children | 40 |
least one | 40 |
critical care | 40 |
lung fields | 40 |
severe respiratory | 40 |
antimicrobial treatment | 40 |
clinical diagnosis | 40 |
radiographic features | 40 |
imaging findings | 40 |
antibiotic use | 40 |
seasonal influenza | 40 |
pneumococcal proteins | 40 |
klebsiella pneumoniae | 39 |
disease caused | 39 |
influenza viruses | 39 |
pasteurella multocida | 39 |
necrotizing pneumonia | 39 |
pulmonary fibrosis | 39 |
recent studies | 39 |
clinical outcomes | 39 |
antigen detection | 39 |
sbt abpc | 39 |
within days | 39 |
influenza pandemic | 39 |
airway obstruction | 39 |
poorly defined | 39 |
infected individuals | 38 |
alveolar walls | 38 |
drug susceptibility | 38 |
british thoracic | 38 |
pandemic influenza | 38 |
pneumococcal bacteremia | 38 |
respiratory samples | 38 |
clinical manifestations | 38 |
pulmonary infiltrates | 38 |
risk patients | 38 |
respiratory viral | 38 |
pleural space | 38 |
eosinophilic pneumonia | 37 |
pulmonary lesions | 37 |
young adults | 37 |
tract disease | 37 |
antimicrobial agents | 37 |
previously healthy | 37 |
may lead | 37 |
factors associated | 37 |
like illness | 37 |
disease severity | 37 |
pneumococcal polysaccharide | 37 |
hadv pneumonia | 37 |
may result | 37 |
oxygen saturation | 37 |
empirical therapy | 37 |
central nervous | 36 |
adults hospitalized | 36 |
diabetes mellitus | 36 |
north america | 36 |
heart disease | 36 |
otitis media | 36 |
foreign bodies | 36 |
fungal infections | 36 |
ventilated patients | 36 |
alveolar damage | 36 |
parapneumonic effusions | 36 |
chronic lung | 36 |
conjugate vaccination | 36 |
resistant pathogens | 36 |
etiologic agent | 36 |
roc auc | 35 |
polysaccharide vaccine | 35 |
negative bacteria | 35 |
acute igg | 35 |
zoster virus | 35 |
inflammatory process | 35 |
without pneumonia | 35 |
liver disease | 35 |
antimicrobial susceptibility | 35 |
severe illness | 35 |
neuraminidase inhibitors | 35 |
round pneumonia | 35 |
acute lower | 35 |
congestive heart | 35 |
adenovirus type | 35 |
pulmonary tuberculosis | 35 |
cirrhotic patients | 35 |
commonly used | 35 |
strong recommendation | 35 |
drug therapy | 35 |
comprehensive molecular | 35 |
causative agent | 35 |
infi ltrates | 35 |
recent study | 34 |
care units | 34 |
sputum culture | 34 |
death certificates | 34 |
mortality among | 34 |
pneumonia mortality | 34 |
minor criteria | 34 |
infl ammatory | 34 |
initial treatment | 34 |
pneumonia include | 34 |
icu patients | 34 |
resistance patterns | 34 |
purulent sputum | 33 |
side effects | 33 |
influenzae type | 33 |
adenovirus pneumonia | 33 |
des patients | 33 |
glass opacities | 33 |
syndrome coronavirus | 33 |
case definition | 33 |
parainfluenza viruses | 33 |
oxygen therapy | 33 |
predictive value | 33 |
etiologic diagnosis | 33 |
moraxella catarrhalis | 33 |
gram staining | 33 |
rapid diagnosis | 33 |
lobar consolidation | 33 |
chronic bronchitis | 33 |
clinical course | 33 |
middle east | 32 |
pulmonary aspergillosis | 32 |
recent years | 32 |
diagnostic accuracy | 32 |
respiratory secretions | 32 |
outpatient treatment | 32 |
previous studies | 32 |
respiratory society | 32 |
nervous system | 32 |
age groups | 32 |
pneumoniae infection | 32 |
high mortality | 32 |
day mortality | 31 |
pneumonic mannheimiosis | 31 |
severity index | 31 |
ventilatorassociated pneumonia | 31 |
intravenous injection | 31 |
coronavirus disease | 31 |
see table | 31 |
hospital mortality | 31 |
may develop | 31 |
organ failure | 31 |
america american | 31 |
invasive aspergillosis | 31 |
south africa | 31 |
domestic animals | 31 |
patients may | 31 |
legionella pneumonia | 31 |
influenza vaccination | 31 |
time pcr | 31 |
controlled trials | 30 |
mannheimia haemolytica | 30 |
cause pneumonia | 30 |
several studies | 30 |
breath sounds | 30 |
pediatric pneumonia | 30 |
stem cell | 30 |
microbial etiology | 30 |
peripheral blood | 30 |
mechanically ventilated | 30 |
diffuse interstitial | 30 |
air bronchogram | 30 |
immune system | 30 |
early stages | 30 |
marrow transplant | 30 |
may show | 30 |
lung infection | 30 |
immunocompromised host | 29 |
pneumoniae pneumonia | 29 |
human immunodeficiency | 29 |
legionella species | 29 |
renal failure | 29 |
immunodeficiency virus | 29 |
lower lung | 29 |
immunosuppressed patients | 29 |
des pac | 29 |
society guidelines | 29 |
previously described | 29 |
resolution ct | 29 |
children hospitalized | 29 |
ciliary dyskinesia | 29 |
clinical stability | 29 |
antigen tests | 29 |
viral respiratory | 29 |
highest mean | 29 |
dans les | 29 |
common causes | 29 |
respiratory diseases | 29 |
older adults | 29 |
clinical outcome | 29 |
global burden | 28 |
legionella spp | 28 |
anaerobic bacteria | 28 |
machine learning | 28 |
upper airway | 28 |
moderate recommendation | 28 |
viral pneumonias | 28 |
middle lobe | 28 |
enzootic pneumonia | 28 |
many patients | 28 |
etiologic agents | 28 |
japanese respiratory | 28 |
adv pneumonia | 28 |
measles virus | 28 |
acute pneumonia | 28 |
respiratory virus | 28 |
consensus guidelines | 28 |
pulse oximetry | 28 |
mean roc | 28 |
pneumococcal infection | 27 |
negative bacilli | 27 |
patients receiving | 27 |
fatal cases | 27 |
lavage fluid | 27 |
oral antibiotics | 27 |
binax now | 27 |
mg dl | 27 |
solid organ | 27 |
idsa ats | 27 |
society consensus | 27 |
pneumoniae urinary | 27 |
increased mortality | 27 |
pleural fl | 27 |
lung markings | 27 |
host defense | 27 |
case report | 27 |
severity assessment | 27 |
randomised controlled | 27 |
recurrent pneumonia | 27 |
within hours | 27 |
influenza vaccine | 27 |
acute bronchitis | 27 |
au cours | 27 |
high fever | 27 |
episodes per | 27 |
high incidence | 27 |
endothelial cells | 27 |
inclusion bodies | 27 |
nipah virus | 27 |
bacterial pneumonias | 27 |
laboratory tests | 26 |
air trapping | 26 |
hemorrhagic fever | 26 |
viral pathogens | 26 |
primary viral | 26 |
clinical trials | 26 |
wbc count | 26 |
abscess formation | 26 |
tracheobronchial tree | 26 |
radiographic appearance | 26 |
treatment failure | 26 |
enteric bacteria | 26 |
lung tissue | 26 |
fibrinous bronchopneumonia | 26 |
otherwise healthy | 26 |
important role | 26 |
pulmonary parenchyma | 26 |
east respiratory | 26 |
pleuritic chest | 26 |
high prevalence | 26 |
chez les | 26 |
based study | 26 |
positive results | 26 |
nasal mucosa | 26 |
scientific production | 26 |
medical conditions | 26 |
empirical antibiotic | 25 |
pleural surface | 25 |
infections caused | 25 |
i pneumonocytes | 25 |
age years | 25 |
study reported | 25 |
guidelines recommend | 25 |
endotracheal tube | 25 |
may present | 25 |
current study | 25 |
critical review | 25 |
observational studies | 25 |
administration period | 25 |
common pathogens | 25 |
glass opacity | 25 |
mortality risk | 25 |
antiviral treatment | 25 |
diagnostic test | 25 |
fi ndings | 25 |
sputum production | 25 |
definitive diagnosis | 25 |
conjugate vaccines | 25 |
suppurative bronchopneumonia | 25 |
chest wall | 25 |
study period | 25 |
term care | 25 |
halo sign | 25 |
pour le | 25 |
may help | 25 |
commonly seen | 25 |
first choices | 25 |
nosocomial infection | 25 |
bronchial wall | 24 |
underlying diseases | 24 |
pulmonary function | 24 |
retrospective study | 24 |
infected patients | 24 |
ground glass | 24 |
requiring intensive | 24 |
infection may | 24 |
upper lobes | 24 |
data suggest | 24 |
informed consent | 24 |
interstitial lung | 24 |
fatality rate | 24 |
two groups | 24 |
present study | 24 |
chronic heart | 24 |
ct scans | 24 |
small airways | 24 |
systematic analysis | 24 |
thoracic cavity | 24 |
interstitial pneumonias | 24 |
child health | 24 |
acute interstitial | 24 |
appropriate antimicrobial | 24 |
lipid pneumonia | 24 |
human parainfluenza | 24 |
pulmonary hypertension | 24 |
performed using | 24 |
lipoid pneumonia | 24 |
chlamydophila pneumoniae | 24 |
necrosis factor | 23 |
connective tissue | 23 |
syndromic rm | 23 |
initial therapy | 23 |
important cause | 23 |
control study | 23 |
primary infection | 23 |
gross lesions | 23 |
positive blood | 23 |
macrolide resistance | 23 |
large number | 23 |
widely used | 23 |
case fatality | 23 |
mg day | 23 |
adults aged | 23 |
first choice | 23 |
confirmed pneumonia | 23 |
executive summary | 23 |
lung lobe | 23 |
en cas | 23 |
atypical bacteria | 23 |
one patient | 23 |
lung cancer | 23 |
sore throat | 23 |
immune responses | 23 |
scoring system | 23 |
pneumonia group | 23 |
case series | 23 |
gold standard | 23 |
laboratory data | 23 |
mononuclear cells | 23 |
usually occurs | 23 |
frequently isolated | 22 |
mucociliary clearance | 22 |
another study | 22 |
care facilities | 22 |
randomized trials | 22 |
mdr pathogens | 22 |
higher mortality | 22 |
cause severe | 22 |
pediatric infectious | 22 |
one year | 22 |
diffi cult | 22 |
pulmonary syndrome | 22 |
supplementary material | 22 |
blood gas | 22 |
transfer learning | 22 |
enteric gram | 22 |
drug resistance | 22 |
specific pathogens | 22 |
il est | 22 |
disease progression | 22 |
pneumocystis carinii | 22 |
smoking cessation | 22 |
patients presenting | 22 |
initial antibiotic | 22 |
second choices | 22 |
airway disease | 22 |
two patients | 22 |
generation cephalosporin | 22 |
pulmonary embolism | 22 |
lesser extent | 22 |
lower mortality | 22 |
prediction rule | 22 |
randomized clinical | 22 |
inflammatory cells | 22 |
clinical findings | 22 |
cavitary necrosis | 22 |
causative organism | 21 |
pneumonia occurs | 21 |
respiratory specimens | 21 |
pneumonia guidelines | 21 |
blood vessels | 21 |
polymicrobial pneumonia | 21 |
pneumonia diagnosis | 21 |
chronic cough | 21 |
pneumonia community | 21 |
healthy children | 21 |
hospitalization among | 21 |
pneumonia associated | 21 |
bordetella bronchiseptica | 21 |
suspected pneumonia | 21 |
human bocavirus | 21 |
mycobacterium avium | 21 |
ng ml | 21 |
chest tube | 21 |
virus type | 21 |
arterial blood | 21 |
low risk | 21 |
function tests | 21 |
nasal discharge | 21 |
pcr assay | 21 |
elderly people | 21 |
viral antigens | 21 |
sputum gram | 21 |
empirical treatment | 21 |
protected specimen | 21 |
hospital treatment | 21 |
pulmonary alveolar | 21 |
infected adults | 21 |
logistic regression | 21 |
polymicrobial etiology | 21 |
centrilobular nodules | 20 |
signifi cant | 20 |
hantavirus pulmonary | 20 |
electron microscopy | 20 |
tumor necrosis | 20 |
underlying lung | 20 |
children may | 20 |
respiratory epithelium | 20 |
major cause | 20 |
alveolar capillaries | 20 |
opportunistic infections | 20 |
prior antibiotic | 20 |
respiratory fluoroquinolone | 20 |
common bacterial | 20 |
two types | 20 |
chronic pulmonary | 20 |
adverse events | 20 |
antiviral agents | 20 |
pediatric intensive | 20 |
bacterial suprainfection | 20 |
gastric contents | 20 |
also cause | 20 |
diagnostic methods | 20 |
interlobular septa | 20 |
patients treated | 20 |
even though | 20 |
severe adv | 20 |
disease may | 20 |
granulomatous pneumonia | 20 |
likelihood ratio | 20 |
less likely | 20 |
taz pipc | 20 |
conducting system | 20 |
pregnant women | 20 |
saharan africa | 20 |
five years | 20 |
multinucleated giant | 20 |
nursing homes | 20 |
appropriate antibiotic | 20 |
pneumococcal vaccine | 20 |
sputum cultures | 20 |
fi rst | 20 |
ats guidelines | 20 |
initial management | 20 |
clinically relevant | 20 |
significantly higher | 20 |
ct features | 19 |
immunocompetent adults | 19 |
day second | 19 |
intubated patients | 19 |
disease burden | 19 |
membrane oxygenation | 19 |
mrsa pneumonia | 19 |
blood samples | 19 |
may produce | 19 |
giant cell | 19 |
parapneumonic effusion | 19 |
kg twice | 19 |
requiring mechanical | 19 |
diagnostic tools | 19 |
significant differences | 19 |
adult respiratory | 19 |
weight loss | 19 |
single dose | 19 |
immunodefi ciency | 19 |
often associated | 19 |
test results | 19 |
may include | 19 |
chest imaging | 19 |
widespread use | 19 |
chest radiographic | 19 |
first days | 19 |
results obtained | 19 |
pneumococcal vaccination | 19 |
may become | 19 |
patients infected | 19 |
may appear | 19 |
children patients | 19 |
infection occurs | 19 |
serum procalcitonin | 19 |
pour les | 19 |
early diagnosis | 19 |
odds ratio | 19 |
nosocomial infections | 19 |
children years | 19 |
gg opacities | 19 |
pulmonary hemorrhage | 19 |
bronchopulmonary aspergillosis | 19 |
congenital heart | 19 |
multicenter study | 19 |
influenza vaccines | 19 |
highly contagious | 19 |
bronchointerstitial pneumonia | 19 |
empirical antimicrobial | 19 |
clinical setting | 19 |
complement fixation | 19 |
outpatient setting | 19 |
primary tuberculosis | 19 |
microscopic examination | 19 |
patients requiring | 19 |
virulence factors | 19 |
endotracheal aspirates | 19 |
infl ammation | 19 |
oral administration | 18 |
prise en | 18 |
respiratory pathogen | 18 |
human infection | 18 |
streptococcus equi | 18 |
bacterial pathogen | 18 |
small number | 18 |
seven days | 18 |
additional file | 18 |
blood count | 18 |
allergic bronchopulmonary | 18 |
care facility | 18 |
pulmonary involvement | 18 |
children older | 18 |
pneumonia episodes | 18 |
causing pneumonia | 18 |
staphylococcal pneumonia | 18 |
abdominal pain | 18 |
medical records | 18 |
fungal infection | 18 |
lymph node | 18 |
prospective observational | 18 |
cfu ml | 18 |
vap rates | 18 |
icu care | 18 |
literature review | 18 |
novel coronavirus | 18 |
disease society | 18 |
incubation period | 18 |
molecular methods | 18 |
children admitted | 18 |
year study | 18 |
lower airways | 18 |
alveolar space | 18 |
level iii | 18 |
severe influenza | 18 |
confirmed influenza | 18 |
pulmonary diseases | 18 |
clinical response | 18 |
cell pneumonia | 18 |
clinical pneumonia | 18 |
empiric antibiotic | 18 |
large numbers | 18 |
cmv pneumonia | 18 |
initial empirical | 18 |
primary ciliary | 18 |
smooth muscle | 18 |
multivariate analysis | 18 |
pneumoniae infections | 18 |
pleural thickening | 18 |
twice daily | 18 |
viral load | 18 |
kg day | 18 |
np carriage | 18 |
per day | 18 |
noninvasive ventilation | 18 |
perch study | 18 |
mm hg | 18 |
year prospective | 18 |
causative agents | 18 |
onset pneumonia | 18 |
influenza season | 18 |
invasive pulmonary | 18 |
initial antimicrobial | 18 |
auc score | 18 |
acquired respiratory | 18 |
underlying medical | 18 |
extracorporeal membrane | 18 |
hyaline membranes | 18 |
pulmonary gangrene | 18 |
immunocompetent patients | 18 |
reference standard | 18 |
prediction rules | 18 |
pulmonary nodules | 18 |
systolic blood | 18 |
advisory committee | 17 |
gas exchange | 17 |
blood cells | 17 |
septal thickening | 17 |
laboratory findings | 17 |
per person | 17 |
causative pathogens | 17 |
infection due | 17 |
resistant streptococcus | 17 |
bacterial co | 17 |
pao fio | 17 |
diagnostic des | 17 |
ray demonstrates | 17 |
pulmonary eosinophilia | 17 |
diffuse bilateral | 17 |
interstitial pneumonitis | 17 |
wall thickening | 17 |
commonly caused | 17 |
causative pathogen | 17 |
respiratory quinolones | 17 |
unit admission | 17 |
economic burden | 17 |
cell transplantation | 17 |
south america | 17 |
lung abscesses | 17 |
situ hybridization | 17 |
live births | 17 |
pathologic features | 17 |
acid amplification | 17 |
nodular opacities | 17 |
total wbc | 17 |
viral causes | 17 |
specimen brush | 17 |
legionnaires disease | 17 |
innate immune | 17 |
viral etiology | 17 |
term mortality | 17 |
lower airway | 17 |
neural network | 17 |
pneumoniae isolates | 17 |
cell culture | 17 |
children less | 17 |
study showed | 17 |
severe covid | 17 |
lung lobes | 17 |
clinical disease | 17 |
clinical effects | 17 |
high levels | 17 |
day course | 17 |
acute exacerbation | 17 |
higher incidence | 17 |
immune status | 17 |
alveolar interstitium | 17 |
host response | 17 |
deep learning | 17 |
frequently detected | 17 |
mean accuracy | 17 |
cardiopulmonary disease | 17 |
urine samples | 17 |
iii evidence | 17 |
en charge | 17 |
serum levels | 17 |
organ transplant | 16 |
primary lung | 16 |
rhodococcus equi | 16 |
patients aged | 16 |
healthy adults | 16 |
data collection | 16 |
legionella infection | 16 |
excess mortality | 16 |
blood eosinophilia | 16 |
three days | 16 |
treatment response | 16 |
infected cells | 16 |
individual patient | 16 |
cases per | 16 |
broad spectrum | 16 |
aspiration pneumonitis | 16 |
susceptibility testing | 16 |
pcr assays | 16 |
mean age | 16 |
pneumonia complicating | 16 |
southeast asia | 16 |
chlamydia psittaci | 16 |
two cases | 16 |
host defenses | 16 |
early treatment | 16 |
among hospitalized | 16 |
pulmonary complications | 16 |
pneumonia detection | 16 |
avec une | 16 |
nonproductive cough | 16 |
cerebrospinal fluid | 16 |
mental status | 16 |
pathogens include | 16 |
chlamydia trachomatis | 16 |
cette technique | 16 |
antimicrobial activity | 16 |
alveolar edema | 16 |
cigarette smoking | 16 |
two days | 16 |
infected children | 16 |
level i | 16 |
also occur | 16 |
complicated pneumonia | 16 |
hematopoietic stem | 16 |
admission decision | 16 |
commercially available | 16 |
frequently identified | 16 |
comorbid conditions | 16 |
pathogenic bacteria | 16 |
rapid diagnostic | 16 |
bts guidelines | 16 |
marrow transplantation | 16 |
resistant strains | 16 |
individual patients | 16 |
united kingdom | 16 |
rapidly progressive | 16 |
pleural cavity | 16 |
mixed infection | 16 |
commonly identified | 16 |
level ii | 16 |
heart rate | 16 |
clinical significance | 16 |
bronchial obstruction | 16 |
urea nitrogen | 16 |
hematogenous dissemination | 16 |
healthy individuals | 16 |
pneumococcal infections | 16 |
hilar adenopathy | 16 |
immunocompromised hosts | 16 |
keyword searching | 16 |
adult pneumonia | 16 |
ethics committee | 15 |
atrophic rhinitis | 15 |
high rates | 15 |
wide range | 15 |
leukocyte count | 15 |
nitric oxide | 15 |
urine antigen | 15 |
roc curve | 15 |
microbiological diagnosis | 15 |
therapy may | 15 |
cap guidelines | 15 |
higher risk | 15 |
lung function | 15 |
avium complex | 15 |
viral culture | 15 |
phagocytic cells | 15 |
identify patients | 15 |
require hospitalization | 15 |
pneumonia date | 15 |
influenza deaths | 15 |
productive cough | 15 |
disease study | 15 |
expectorated sputum | 15 |
pneumococcal serotypes | 15 |
patient age | 15 |
negative organisms | 15 |
frequent cause | 15 |
microbiological investigations | 15 |
conventional culture | 15 |
care medicine | 15 |
disease associated | 15 |
burkholderia pseudomallei | 15 |
breaths min | 15 |
body temperature | 15 |
inhalational anthrax | 15 |
hospitalised patients | 15 |
gastric acid | 15 |
basement membrane | 15 |
organ transplantation | 15 |
hospital admissions | 15 |
infected persons | 15 |
mediastinal lymph | 15 |
treatment period | 15 |
multiplex polymerase | 15 |
usually associated | 15 |
bronchial pneumonia | 15 |
intranuclear inclusion | 15 |
vital signs | 15 |
must also | 15 |
convolutional neural | 15 |
blood urea | 15 |
host immune | 15 |
acquired bacterial | 15 |
clinical suspicion | 15 |
controlled clinical | 15 |
acute pulmonary | 15 |
endogenous lipid | 15 |
cellular debris | 15 |
lung lesions | 15 |
microscopic lesions | 15 |
pneumonia remains | 15 |
resistant organisms | 15 |
atypical organisms | 15 |
antigen testing | 15 |
per year | 15 |
clinical efficacy | 15 |
cours des | 15 |
il faut | 15 |
care settings | 15 |
table shows | 15 |
disease due | 15 |
klebsiella spp | 15 |
dans le | 15 |
general population | 15 |
pneumocystis jiroveci | 15 |
underlying conditions | 15 |
resistance among | 15 |
mycobacterium bovis | 15 |
spectrum antibiotic | 15 |
progressive pneumonia | 15 |
new quinolones | 15 |
pneumonia panel | 15 |
days later | 15 |
du traitement | 15 |
renal transplant | 15 |
single cell | 15 |
first hours | 15 |
studies suggest | 15 |
une pneumonie | 15 |
modifying factors | 15 |
endotracheal aspirate | 15 |
pour une | 15 |
people aged | 15 |
similar results | 15 |
vaccine efficacy | 14 |
one third | 14 |
immunocompromised children | 14 |
diagnostic value | 14 |
lung infections | 14 |
quantitative culture | 14 |
like symptoms | 14 |
diagnostic yield | 14 |
including pneumonia | 14 |
equine influenza | 14 |
steroid therapy | 14 |
several factors | 14 |
clinical data | 14 |
interstitial fibrosis | 14 |
aureus pneumonia | 14 |
dendritic cells | 14 |
ii evidence | 14 |
clinical impact | 14 |
reverse transcriptase | 14 |
molecular diagnostics | 14 |
corticosteroid therapy | 14 |
hospital discharge | 14 |
right lower | 14 |
paranasal sinuses | 14 |
identifi ed | 14 |
center study | 14 |
mean sensitivity | 14 |
infl uenzae | 14 |
endotracheal intubation | 14 |
turnaround time | 14 |
bloodstream infections | 14 |
disease among | 14 |
approximately days | 14 |
infectious agents | 14 |
may require | 14 |
bronchoscopic bal | 14 |
multiplex real | 14 |
clinical specimens | 14 |
selected patients | 14 |
histoplasma capsulatum | 14 |
alveolar spaces | 14 |
old woman | 14 |
cell rna | 14 |
neonatal pneumonia | 14 |
comorbid illness | 14 |
drotrecogin alfa | 14 |
child mortality | 14 |
section ct | 14 |
sur le | 14 |
combination antibiotic | 14 |
squamous metaplasia | 14 |
high proportion | 14 |
adverse effects | 14 |
epidemiological studies | 14 |
also associated | 14 |
gastroesophageal reflux | 14 |
new diagnostic | 14 |
may increase | 14 |
close contact | 14 |
defi ned | 14 |
lactam plus | 14 |
uncomplicated influenza | 14 |
vitro resistance | 14 |
empirical regimen | 14 |
valentine leukocidin | 14 |
cellular analysis | 14 |
neural networks | 14 |
major criteria | 14 |
pneumonia pathogens | 14 |
clinical deterioration | 14 |
i evidence | 14 |
regression analysis | 14 |
invasive disease | 14 |
nasal passages | 14 |
scoring systems | 14 |
bronchopleural fistula | 14 |
nasal swabs | 14 |
rural areas | 14 |
pulmonary abscesses | 14 |
randomized study | 14 |
obstructive lung | 14 |
approximately one | 14 |
fully connected | 14 |
medical history | 14 |
antiviral drugs | 14 |
two drugs | 14 |
rarely seen | 14 |
several days | 14 |
positive predictive | 14 |
pneumococcal vaccines | 14 |
elderly persons | 14 |
gastrointestinal tract | 14 |
convnet experiments | 14 |
pathogens isolated | 14 |
mycobacterium infection | 14 |
mean specificity | 14 |
patient outcomes | 14 |
hospitalized adults | 14 |
infection caused | 14 |
east asia | 14 |
pneumonia based | 14 |
attributable mortality | 14 |
lactamase inhibitor | 14 |
death records | 14 |
guttural pouch | 14 |
cryptococcus neoformans | 14 |
pneumonia severe | 14 |
reduce mortality | 14 |
human adenovirus | 14 |
pneumonia deaths | 14 |
bacterial causes | 14 |
antiretroviral therapy | 14 |
mycobacterial infections | 14 |
mononuclear cell | 14 |
obtained using | 14 |
septic emboli | 14 |
physical findings | 13 |
european countries | 13 |
crp level | 13 |
rapid detection | 13 |
viral pcr | 13 |
mr imaging | 13 |
hospital acquired | 13 |
atypical bacterial | 13 |
granulomatous disease | 13 |
median age | 13 |
human disease | 13 |
diagnostic criteria | 13 |
bacterial cap | 13 |
fiberoptic bronchoscopy | 13 |
respiratory signs | 13 |
host factors | 13 |
ventilator associated | 13 |
le traitement | 13 |
patients received | 13 |
whole blood | 13 |
often seen | 13 |
require hospital | 13 |
causative organisms | 13 |
fluid total | 13 |
diagnostic techniques | 13 |
bacterial superinfection | 13 |
mucoid impaction | 13 |
north american | 13 |
treatment options | 13 |
potential pathogens | 13 |
japanese society | 13 |
pneumonia classification | 13 |
interquartile range | 13 |
molecular diagnostic | 13 |
necrotizing bronchiolitis | 13 |
study indicated | 13 |
induced sputum | 13 |
pilot study | 13 |
poor outcome | 13 |
may improve | 13 |
commonly found | 13 |
acute onset | 13 |
auc scores | 13 |
glass attenuation | 13 |
usually present | 13 |
positive likelihood | 13 |
barr virus | 13 |
initial phase | 13 |
mrsa infection | 13 |
ipm cs | 13 |
appropriate antibiotics | 13 |
authors declare | 13 |
imaging features | 13 |
cap cases | 13 |
organ dysfunction | 13 |
lung changes | 13 |
multiple organ | 13 |
limited number | 13 |
cell counts | 13 |
left lower | 13 |
early stage | 13 |
radiological findings | 13 |
erythrocyte sedimentation | 13 |
developed countries | 13 |
high morbidity | 13 |
innate immunity | 13 |
cd counts | 13 |
frequently seen | 13 |
million deaths | 13 |
invasive ventilation | 13 |
developing world | 13 |
lung microbiome | 13 |
copies ml | 13 |
clinical evaluation | 13 |
coxiella burnetii | 13 |
mycoplasmal pneumonia | 13 |
canine distemper | 13 |
much higher | 13 |
statistically significant | 13 |
right middle | 13 |
organisms may | 13 |
may take | 13 |
aspergillus fumigatus | 13 |
acinetobacter spp | 13 |
pulmonary surfactant | 13 |
fdr correction | 13 |
parainfl uenza | 13 |
also occurs | 13 |
winter months | 13 |
adjuvant therapy | 13 |
validation study | 13 |
supportive care | 13 |
also found | 13 |
see section | 13 |
received antibiotics | 13 |
cidofovir administration | 13 |
overall mortality | 13 |
une pac | 13 |
free radicals | 13 |
interlobular septal | 13 |
diffuse panbronchiolitis | 13 |
generation cephalosporins | 13 |
positive bacteria | 13 |
bordetella pertussis | 13 |
closely related | 13 |
less frequently | 13 |
rsv bronchiolitis | 13 |
bacterial cause | 13 |
tract samples | 13 |
positive patients | 13 |
older patients | 13 |
admitted patients | 13 |
alveolar infiltrates | 13 |
antibiotic administration | 13 |
molecular tests | 13 |
may reveal | 13 |
alveolar injury | 13 |
pneumonia pneumonia | 13 |
recently published | 13 |
treatment strategies | 13 |
neuraminidase inhibitor | 13 |
pattern recognition | 13 |
pneumococcal antigen | 13 |
likely pathogens | 13 |
diagnostic microbiologique | 13 |
des cas | 13 |
room air | 13 |
pulmonary artery | 12 |
clinical settings | 12 |
tuberculosis infection | 12 |
st combination | 12 |
airspace consolidation | 12 |
study protocol | 12 |
neonatal period | 12 |
initial presentation | 12 |
infectious respiratory | 12 |
mineral oil | 12 |
specific pathogen | 12 |
canine infectious | 12 |
associated complications | 12 |
urban areas | 12 |
dry cough | 12 |
explorations microbiologiques | 12 |
aspiration risk | 12 |
pleural adhesions | 12 |
pathogenic microorganisms | 12 |
severe pneumococcal | 12 |
develop pneumonia | 12 |
tract symptoms | 12 |
international guidelines | 12 |
wide variety | 12 |
virus detection | 12 |
inflammatory biomarkers | 12 |
hyaline membrane | 12 |
antibiotic susceptibility | 12 |
among hiv | 12 |
confidence interval | 12 |
inflammatory cytokines | 12 |
les pneumonies | 12 |
mg ml | 12 |
least two | 12 |
made based | 12 |
viral agents | 12 |
cytomegalovirus infection | 12 |
well documented | 12 |
needle aspiration | 12 |
endemic areas | 12 |
including patients | 12 |
many years | 12 |
pacific region | 12 |
case definitions | 12 |
common pathogen | 12 |
rna viruses | 12 |
higher rates | 12 |
disseminated intravascular | 12 |
influenza cases | 12 |
environmental factors | 12 |
high sensitivity | 12 |
varicella zoster | 12 |
chemical pneumonitis | 12 |
lung involvement | 12 |
sputum sample | 12 |
relatively low | 12 |
valent pcv | 12 |
tracheal aspirate | 12 |
bud pattern | 12 |
antibiotic prescribing | 12 |
oral care | 12 |
postmortem examination | 12 |
new antibiotics | 12 |
cor pulmonale | 12 |
sedimentation rate | 12 |
tracheal aspirates | 12 |
liver function | 12 |
wilcoxon rank | 12 |
interpandemic influenza | 12 |
negative bacillus | 12 |
respiratory medicine | 12 |
pneumocystis jirovecii | 12 |
frequently associated | 12 |
negative predictive | 12 |
cmv infection | 12 |
tuberculous mycobacterium | 12 |
early childhood | 12 |
pulmonary arteries | 12 |
parasitic diseases | 12 |
quantitative cultures | 12 |
hospital care | 12 |
surveillance system | 12 |
patients undergoing | 12 |
visceral pleura | 12 |
viral community | 12 |
lung field | 12 |
microbial aetiology | 12 |
air barrier | 12 |
systemic inflammatory | 12 |
common complication | 12 |
antibody response | 12 |
effective therapy | 12 |
patient management | 12 |
standard culture | 12 |
distemper virus | 12 |
cap requiring | 12 |
general hospital | 12 |
less commonly | 12 |
radiologic findings | 12 |
common clinical | 12 |
monoclonal antibody | 12 |
one case | 12 |
mycoplasma hyopneumoniae | 12 |
control measures | 12 |
immunization practices | 12 |
three patients | 12 |
electronic death | 12 |
cap incidence | 12 |
two major | 12 |
home residents | 12 |
medical care | 12 |
working group | 12 |
lobular pneumonia | 12 |
open lung | 12 |
american journal | 12 |
psi score | 12 |
comorbidity status | 12 |
global health | 12 |
identify low | 12 |
oropharyngeal secretions | 12 |
published studies | 12 |
invasive mechanical | 12 |
tracheoesophageal fistula | 12 |
annual incidence | 12 |
guttural pouches | 12 |
producing bacteria | 12 |
clinical improvement | 12 |
every hours | 12 |
increased susceptibility | 12 |
sur des | 12 |
negative enteric | 12 |
routine methods | 12 |
acquired pneumonias | 12 |
dans une | 12 |
bronchial mucosa | 12 |
random forest | 12 |
findings include | 12 |
par une | 12 |
patients will | 12 |
incidence rates | 12 |
lung transplant | 12 |
adjunctive therapy | 12 |
also important | 12 |
often fatal | 12 |
radiographic evidence | 12 |
primary cause | 12 |
serologic testing | 12 |
antibody titer | 12 |
acquired infections | 12 |
care workers | 12 |
inflammatory mediators | 12 |
mycoplasma infection | 12 |
francisella tularensis | 12 |
cardiovascular disease | 12 |
lung biopsies | 12 |
plus either | 12 |
viral replication | 12 |
retrospective cohort | 12 |
pneumonia controls | 12 |
cytomegalovirus pneumonia | 12 |
complicating influenza | 12 |
military recruits | 12 |
children without | 12 |
clavulanic acid | 12 |
south asia | 12 |
antimicrobial stewardship | 12 |
disease process | 12 |
may vary | 12 |
ill children | 12 |
include fever | 12 |
routine use | 12 |
pneumonia without | 12 |
pulmonary manifestations | 12 |
nucleic acids | 12 |
cardiac disease | 12 |
empiric treatment | 12 |
idiopathic pulmonary | 12 |
available data | 12 |
medicare patients | 11 |
also reported | 11 |
bal fluids | 11 |
soft tissue | 11 |
macrolide therapy | 11 |
asymptomatic children | 11 |
lobe syndrome | 11 |
scrub typhus | 11 |
severity scores | 11 |
sputum specimens | 11 |
clinical examination | 11 |
type pneumocytes | 11 |
likelihood ratios | 11 |
first described | 11 |
secondary infection | 11 |
pneumonia study | 11 |
bacterial resistance | 11 |
retrospective studies | 11 |
microbiological findings | 11 |
alfa activated | 11 |
grade fever | 11 |
acute phase | 11 |
south korea | 11 |
now streptococcus | 11 |
pathogen identification | 11 |
requiring icu | 11 |
death registration | 11 |
lung infiltrates | 11 |
pneumonia effect | 11 |
require mechanical | 11 |
common cold | 11 |
case management | 11 |
pulmonary defense | 11 |
pneumonia normal | 11 |
resistance genes | 11 |
transplant recipient | 11 |
aids patients | 11 |
probable bacterial | 11 |
nodes may | 11 |
necrotic lung | 11 |
normal images | 11 |
clinical entity | 11 |
korean military | 11 |
intranuclear inclusions | 11 |
acute infection | 11 |
predicting mortality | 11 |
human influenza | 11 |
among elderly | 11 |
en institution | 11 |
normal lung | 11 |
hospital setting | 11 |
acute physiology | 11 |
will require | 11 |
bal samples | 11 |
des pneumonies | 11 |
secretion drainage | 11 |
death certificate | 11 |
per minute | 11 |
immunocompromised adults | 11 |
written informed | 11 |
ray findings | 11 |
specific diagnosis | 11 |
fio ratio | 11 |
acute eosinophilic | 11 |
les auteurs | 11 |
younger children | 11 |
pathologic findings | 11 |
spectrum antimicrobial | 11 |
lung abnormalities | 11 |
hypoxemic patients | 11 |
mixed viral | 11 |
study population | 11 |
icu pneumonia | 11 |
pneumonia refers | 11 |
viruses may | 11 |
medical center | 11 |
currently available | 11 |
reverse transcription | 11 |
plasma cells | 11 |
clinical information | 11 |
mycoplasma spp | 11 |
viral bronchiolitis | 11 |
left upper | 11 |
gas analysis | 11 |
high frequency | 11 |
patients ayant | 11 |
receptor expressed | 11 |
pathogens identified | 11 |
severe sars | 11 |
uk alert | 11 |
susceptibility tests | 11 |
predisposing factors | 11 |
pneumonia usually | 11 |
bacterial organisms | 11 |
pandemic flu | 11 |
renal disease | 11 |
unit patients | 11 |
supplemental oxygen | 11 |
current status | 11 |
pneumonia viral | 11 |
bronchial tree | 11 |
radiologically confirmed | 11 |
frequently observed | 11 |
normal host | 11 |
enlarged lymph | 11 |
pulmonary inflammation | 11 |
committee members | 11 |
vasopressor support | 11 |
intravascular macrophages | 11 |
diagnostic tool | 11 |
amniotic fluid | 11 |
rapid antigen | 11 |
interstitial changes | 11 |
based surveillance | 11 |
regional lymph | 11 |
immunodefi ciencies | 11 |
pneumonia images | 11 |
hendra virus | 11 |
artificial intelligence | 11 |
chest indrawing | 11 |
crescent sign | 11 |
study conducted | 11 |
antibiotic stewardship | 11 |
cell infiltrates | 11 |
viral rna | 11 |
also present | 11 |
multiple nodules | 11 |
children clinical | 11 |
traction bronchiectasis | 11 |
international derivation | 11 |
pneumonies acquises | 11 |
observational cohort | 11 |
positive result | 11 |
negative pressure | 11 |
included patients | 11 |
antibiotic regimen | 11 |
hematogenous spread | 11 |
bronchial arteries | 11 |
high rate | 11 |
acid aspiration | 11 |
myeloid cells | 11 |
time polymerase | 11 |
negative likelihood | 11 |
prospective studies | 11 |
herpes zoster | 11 |
pneumonia related | 11 |
membrane formation | 11 |
infectious causes | 11 |
microbiological tests | 11 |
cellular immunity | 11 |
associated events | 11 |
supplementary table | 11 |
exact test | 11 |
military training | 11 |
flow cytometry | 11 |
positive cocci | 11 |
many countries | 11 |
prognostic factors | 11 |
cause disease | 11 |
directed therapy | 11 |
risk classes | 11 |
surveillance data | 11 |
triggering receptor | 11 |
le plus | 11 |
alveolar proteinosis | 11 |
patients admis | 11 |
parapneumonic empyema | 11 |
affected lung | 11 |
fluorescent antibody | 11 |
consecutive patients | 11 |
bacterial coinfection | 11 |
th day | 11 |
mediated immunity | 11 |
military trainees | 11 |
soluble triggering | 11 |
campbell syndrome | 11 |
clinical severity | 11 |
many children | 11 |
detected using | 11 |
rheumatoid arthritis | 11 |
hazard ratio | 11 |
initial empiric | 11 |
lymphatic vessels | 11 |
cd count | 11 |
mac infection | 11 |
subglottic secretion | 11 |
swine influenza | 11 |
hospitalized infants | 11 |
metapneumovirus infection | 11 |
fi brosis | 11 |
patient populations | 11 |
recent advances | 11 |
diagnose vap | 11 |
carinii pneumonia | 10 |
clotted blood | 10 |
radiologic manifestations | 10 |
retropharyngeal lymph | 10 |
em adultos | 10 |
defined nodular | 10 |
pode ser | 10 |
air crescent | 10 |
oral cavity | 10 |
vast majority | 10 |
enzyme immunoassay | 10 |
related deaths | 10 |
adults admitted | 10 |
comparative study | 10 |
examination findings | 10 |
agents causing | 10 |
chronic granulomatous | 10 |
death among | 10 |
pulmonary vessels | 10 |
antibiotic exposure | 10 |
streptococcus pneumonia | 10 |
see figs | 10 |
later stages | 10 |
primary influenza | 10 |
bacterial respiratory | 10 |
related mortality | 10 |
year old | 10 |
epidemiologic studies | 10 |
candida spp | 10 |
severe pulmonary | 10 |
intravascular coagulation | 10 |
improved within | 10 |
collateral ventilation | 10 |
also referred | 10 |
fluid cellular | 10 |
pneumonia occurring | 10 |
institutional affiliations | 10 |
hospitalacquired pneumonia | 10 |
allergic alveolitis | 10 |
gastrointestinal symptoms | 10 |
specific antibodies | 10 |
specifi city | 10 |
usually occur | 10 |
hypersensitivity pneumonitis | 10 |
resolution computed | 10 |
cough reflex | 10 |
time period | 10 |
prospective randomized | 10 |
pneumonia using | 10 |
quantitative pcr | 10 |
reactivation tuberculosis | 10 |
study investigators | 10 |
en compte | 10 |
adjusted odds | 10 |
pathogens may | 10 |
apache ii | 10 |
radiographic manifestations | 10 |
oral hygiene | 10 |
underlying cause | 10 |
lactate dehydrogenase | 10 |
blood pcr | 10 |
des techniques | 10 |
retrospective analysis | 10 |
syndromic molecular | 10 |
pcr testing | 10 |
resistant mycoplasma | 10 |
microbial diagnosis | 10 |
past months | 10 |
i interferon | 10 |
bronchopulmonary dysplasia | 10 |
bronchial walls | 10 |
elderly cap | 10 |
human infections | 10 |
real time | 10 |
defining community | 10 |
hypoxemic pneumonia | 10 |
alveolar epithelium | 10 |
organism may | 10 |
beats min | 10 |
primary atypical | 10 |
newly recognized | 10 |
patient groups | 10 |
case reports | 10 |
mortality due | 10 |
streptococcus pyogenes | 10 |
immune function | 10 |
cva ampc | 10 |
resistant microorganisms | 10 |
cutoff value | 10 |
airway pressure | 10 |
pneumonia per | 10 |
studies reported | 10 |
mesh terms | 10 |
equine viral | 10 |
university hospital | 10 |
two different | 10 |
plasma proteins | 10 |
infections due | 10 |
one virus | 10 |
lateral decubitus | 10 |
outpatient clinic | 10 |
tds iv | 10 |
take oral | 10 |
trained networks | 10 |
human adv | 10 |
par le | 10 |
prospective cohort | 10 |
inhibitory concentration | 10 |
pneumococcal immunization | 10 |
limited data | 10 |
pulmonary pathogens | 10 |
transbronchial biopsy | 10 |
treatment guidelines | 10 |
corona virus | 10 |
foreign material | 10 |
immunization schedule | 10 |
focal pneumonia | 10 |
previously reported | 10 |
infection among | 10 |
induced pulmonary | 10 |
les recommandations | 10 |
influenzarelated pneumonia | 10 |
childhood community | 10 |
allergic patients | 10 |
acute influenza | 10 |
antibiotic regimens | 10 |
develop severe | 10 |
type infection | 10 |
median length | 10 |
national causes | 10 |
extensive diagnostic | 10 |
initial chest | 10 |
ct imaging | 10 |
institutional review | 10 |
exogenous lipid | 10 |
general practitioner | 10 |
laboratory diagnosis | 10 |
inspired oxygen | 10 |
surveillance study | 10 |
lobular atelectasis | 10 |
air bronchograms | 10 |
specific risk | 10 |
chronic interstitial | 10 |
complete blood | 10 |
without hiv | 10 |
hypersensitivity reaction | 10 |
may provide | 10 |
univariate analysis | 10 |
cell wall | 10 |
cause mortality | 10 |
adult community | 10 |
following criteria | 10 |
admis en | 10 |
infectious agent | 10 |
embolic pneumonia | 10 |
canine influenza | 10 |
parenchymal consolidation | 10 |
aged children | 10 |
patient population | 10 |
cut surface | 10 |
different types | 10 |
year period | 10 |
elderly individuals | 10 |
significantly associated | 10 |
respiratory coronavirus | 10 |
clinical criteria | 10 |
mg times | 10 |
pneumonia secondary | 10 |
streptococcus spp | 10 |
influenza epidemic | 10 |
oseltamivir treatment | 10 |
multicenter trial | 10 |
agents may | 10 |
symptoms may | 10 |
agents include | 10 |
acute renal | 10 |
bacterial coinfections | 10 |
determine whether | 10 |
descriptive study | 10 |
pneumonia treatment | 10 |
recurrent respiratory | 10 |
hiv aids | 10 |
pneumonia evaluation | 10 |
chronic liver | 10 |
multiple pathogens | 10 |
underlying chronic | 10 |
aspergillus spp | 10 |
intermediate hosts | 10 |
bulk rna | 10 |
cough may | 10 |
adjacent lung | 10 |
childhood immunization | 10 |
serum samples | 10 |
lung parenchymal | 10 |
clinical study | 10 |
frequently used | 10 |
previous study | 10 |
empirical coverage | 10 |
effective treatment | 10 |
pulmonary aspiration | 10 |
oral amoxicillin | 10 |
bacterial etiology | 10 |
procalcitonin concentration | 10 |
lymph vessels | 10 |
acquired immunodeficiency | 10 |
patan hospital | 10 |
immunodeficiency syndrome | 10 |
tissue culture | 10 |
chronic disease | 10 |
pneumonia burden | 10 |
uncomplicated pneumonia | 10 |
also known | 10 |
pneumococcal cap | 10 |
lactam agents | 10 |
hsv infection | 10 |
cohort studies | 10 |
disseminated disease | 10 |
antibiotic dose | 10 |
hpiv pneumonia | 10 |
controlled studies | 10 |
signifi cantly | 10 |
producing strains | 10 |
rsv infection | 10 |
may suggest | 10 |
large amounts | 10 |
intravenous fluids | 10 |
pulmonary injury | 10 |
proposed model | 10 |
positive pneumonia | 10 |
diagnostic procedures | 10 |
antibacterial agents | 10 |
ce test | 10 |
incidence rate | 10 |
transthoracic needle | 10 |
diagnostic performance | 10 |
body weight | 10 |
median time | 10 |
intracranial pressure | 10 |
airway inflammation | 10 |
ml clotted | 10 |
common among | 10 |
third trimester | 10 |
adenovirus infections | 10 |
significant difference | 10 |
different countries | 10 |
independently associated | 10 |
antimicrobial chemotherapy | 10 |
increased number | 10 |
samples obtained | 10 |
cells ml | 10 |
definitive therapy | 10 |
positive viral | 9 |
negative pathogens | 9 |
typical bacterial | 9 |
also observed | 9 |
become confluent | 9 |
children presenting | 9 |
bacteremia among | 9 |
bronchiectasis may | 9 |
nasal flora | 9 |
commonly associated | 9 |
rsv pneumonia | 9 |
severely affected | 9 |
pulmonary consolidation | 9 |
diffuse pulmonary | 9 |
radiographic changes | 9 |
pneumococcal urinary | 9 |
particulate matter | 9 |
radiographs show | 9 |
early detection | 9 |
primarily caused | 9 |
based methods | 9 |
cell transplant | 9 |
colleagues found | 9 |
typically present | 9 |
routine childhood | 9 |
rna virus | 9 |
enterobacter spp | 9 |
frequently caused | 9 |
human rhinovirus | 9 |
whooping cough | 9 |
clinical risk | 9 |
predict mortality | 9 |
findings suggest | 9 |
producing enterobacteriaceae | 9 |
complete resolution | 9 |
pulmonary congestion | 9 |
shipping fever | 9 |
respiratory illnesses | 9 |
convolutional layers | 9 |
right lung | 9 |
cap management | 9 |
prospective multicenter | 9 |
two studies | 9 |
acute air | 9 |
fixation test | 9 |
categorical variables | 9 |
natural language | 9 |
hypoxemic respiratory | 9 |
antitrypsin deficiency | 9 |
prospective comparison | 9 |
pulmonary lobes | 9 |
bacterial load | 9 |
multidisciplinary committee | 9 |
differ among | 9 |
etiological diagnosis | 9 |
clinical prediction | 9 |
antibiotic selection | 9 |
interstitial edema | 9 |
immunomodulatory effects | 9 |
scan demonstrates | 9 |
epic study | 9 |
bloody sputum | 9 |
streptococcus suis | 9 |
first antibiotic | 9 |
without underlying | 9 |
right upper | 9 |
immotile cilia | 9 |
antibody responses | 9 |
combined immunodeficiency | 9 |
acute bacterial | 9 |
published guidelines | 9 |
diffuse reticulonodular | 9 |
features include | 9 |
naphthol fast | 9 |
tracheal intubation | 9 |
des infections | 9 |
airways disease | 9 |
bacterial colonization | 9 |
chronic inflammatory | 9 |
chronic pneumonia | 9 |
failure requiring | 9 |
amoxicillin clavulanate | 9 |
noninvasive sampling | 9 |
adult population | 9 |
cryptogenic organizing | 9 |
immunocompromised individuals | 9 |
fast bacilli | 9 |
immune cells | 9 |
creative commons | 9 |
patients died | 9 |
positive cultures | 9 |
decision support | 9 |
parapneumonic pleural | 9 |
important causes | 9 |
control studies | 9 |
permeability edema | 9 |
adaptive immune | 9 |
susceptibility patterns | 9 |
first dose | 9 |
often difficult | 9 |
aspirated foreign | 9 |
experimental studies | 9 |
bovine pleuropneumonia | 9 |
requiring admission | 9 |
cap include | 9 |
hrct findings | 9 |
widely available | 9 |
constrictive bronchiolitis | 9 |
pneumonia treated | 9 |
another important | 9 |
pcr results | 9 |
systemic infection | 9 |
receiving mechanical | 9 |
illness severity | 9 |
bronchiolar epithelium | 9 |
pneumonia rapid | 9 |
microbial agents | 9 |
nodules may | 9 |
thoracoscopic surgery | 9 |
atypical pathogen | 9 |
clinical condition | 9 |
risk groups | 9 |
asian influenza | 9 |
le test | 9 |
levofloxacin mg | 9 |
pulmonary mac | 9 |
suspected vap | 9 |
pathogens causing | 9 |
old man | 9 |
young infants | 9 |
alveolar wall | 9 |
feature vector | 9 |
decreased breath | 9 |
en raison | 9 |
molecular assays | 9 |
pneumonia research | 9 |
fatal pneumonia | 9 |
anaerobic organisms | 9 |
inflammatory reaction | 9 |
hematoxylin counterstain | 9 |
extrinsic allergic | 9 |
lactam antibiotics | 9 |
chronic illness | 9 |
pediatric population | 9 |
diagnostic rapide | 9 |
alveolar hemorrhage | 9 |
nontuberculous mycobacteria | 9 |
alveolar epithelial | 9 |
significantly lower | 9 |
review board | 9 |
respiratory epithelial | 9 |
pulmonary emphysema | 9 |
als assay | 9 |
recurrent infections | 9 |
au niveau | 9 |
microbiological data | 9 |
chronic renal | 9 |
findings may | 9 |
world bank | 9 |
double blind | 9 |
pediatric community | 9 |
squamous epithelium | 9 |
alveolar pneumonia | 9 |
sum tests | 9 |
intravenous therapy | 9 |
bilateral patchy | 9 |
interstitial infiltrates | 9 |
liver dysfunction | 9 |
hyperinfl ation | 9 |
requiring hospital | 9 |
university hospitals | 9 |
increased incidence | 9 |
pneumonia clinical | 9 |
virus influenza | 9 |
repeat chest | 9 |
microbiological investigation | 9 |
often used | 9 |
superior segment | 9 |
antimicrobial activities | 9 |
open access | 9 |
nontuberculous mycobacterial | 9 |
studies showed | 9 |
also may | 9 |
new cases | 9 |
chronic cases | 9 |
leading causes | 9 |
mortality associated | 9 |
decisions regarding | 9 |
direct detection | 9 |
bovine respiratory | 9 |
times higher | 9 |
significantly increased | 9 |
monoclonal antibodies | 9 |
patients also | 9 |
rapid flu | 9 |
learning models | 9 |
ats idsa | 9 |
bilateral diffuse | 9 |
large proportion | 9 |
pulmonary neoplasms | 9 |
management strategies | 9 |
major causes | 9 |
caudal lobes | 9 |
bronchovascular bundles | 9 |
tertiary care | 9 |
inflammatory changes | 9 |
clinical pulmonary | 9 |
plupart des | 9 |
penicillin resistance | 9 |
low mortality | 9 |
bacteremic pneumonia | 9 |
ct scanning | 9 |
drug administration | 9 |
bacterial cultures | 9 |
radiographic resolution | 9 |
remains unclear | 9 |
interstitial emphysema | 9 |
antimicrobial agent | 9 |
oxygen concentration | 9 |
acinetobacter species | 9 |
lymphoid hyperplasia | 9 |
antibody titers | 9 |
pneumonia risk | 9 |
continuous variables | 9 |
pneumonia also | 9 |
hospitalized cases | 9 |
infections may | 9 |
cap admitted | 9 |
diagnosing pneumonia | 9 |
mainland china | 9 |
cell responses | 9 |
methenamine silver | 9 |
porcine pleuropneumonia | 9 |
histophilus somni | 9 |
within weeks | 9 |
local health | 9 |
variably sized | 9 |
cap treatment | 9 |
cardiac complications | 9 |
data analysis | 9 |
respiratory function | 9 |
miliary tuberculosis | 9 |
listeria monocytogenes | 9 |
hospitalized cap | 9 |
empiric antibiotics | 9 |
multidrug resistant | 9 |
fluid level | 9 |
immune deficiency | 9 |
podem ser | 9 |
particularly important | 9 |
deaths per | 9 |
pneumococcal resistance | 9 |
measles infection | 9 |
updated systematic | 9 |
competing interests | 9 |
normal lungs | 9 |
mediastinal lymphadenopathy | 9 |
bacterial tracheitis | 9 |
alveolar lumens | 9 |
cochrane review | 9 |
practice guideline | 9 |
induced lung | 9 |
immunoalkaline phosphatase | 9 |
general condition | 9 |
guided therapy | 9 |
immune systems | 9 |
past years | 9 |
mulbsta score | 9 |
rank sum | 9 |
bacterial meningitis | 9 |
human cases | 9 |
canine adenovirus | 9 |
appropriate treatment | 9 |
dans un | 9 |
chest computed | 9 |
dans des | 9 |
secondary infections | 9 |
controlled study | 9 |
protein antigens | 9 |
asian countries | 9 |
direct fluorescent | 9 |
clinical studies | 9 |
chez des | 9 |
recent systematic | 9 |
pulmonary symptoms | 9 |
early administration | 9 |
alveolar fibrosis | 9 |
affected lungs | 9 |
patients often | 9 |
focal consolidation | 9 |
statistical measurement | 9 |
consensus statement | 8 |
may reduce | 8 |
examination revealed | 8 |
pressure ventilation | 8 |
exercise intolerance | 8 |
pulmonary infectious | 8 |
defense mechanism | 8 |
thoracic radiographs | 8 |
contagious bovine | 8 |
hepatic dysfunction | 8 |
ciliated cells | 8 |
selon le | 8 |
etiology research | 8 |
bacterial growth | 8 |
remains controversial | 8 |
pneumocystis pneumonia | 8 |
pneumoniae antigen | 8 |
skin lesions | 8 |
entre les | 8 |
learning experiments | 8 |
pulmonary vasculature | 8 |
microbiological results | 8 |
particularly high | 8 |
sweat chloride | 8 |
negative results | 8 |
reduced mortality | 8 |
final manuscript | 8 |
requiring vasopressors | 8 |
laryngeal hemiplegia | 8 |
klebsiella pneumonia | 8 |
ct halo | 8 |
poorly understood | 8 |
younger adults | 8 |
early recognition | 8 |
systematic reviews | 8 |
jiroveci pneumonia | 8 |
severe hypoxemia | 8 |
patient data | 8 |
pathogens responsible | 8 |
chapter will | 8 |
higher proportion | 8 |
mg bd | 8 |
tropical pulmonary | 8 |
lung aspiration | 8 |
diagnostic laboratories | 8 |
host disease | 8 |
cytokine response | 8 |
nonbacterial pneumonia | 8 |
trapped lung | 8 |
using pcr | 8 |
first year | 8 |
tous les | 8 |
associated coronavirus | 8 |
exclusion criteria | 8 |
mtb rif | 8 |
pneumonia case | 8 |
rapid urinary | 8 |
pneumococcal protein | 8 |
aspergillus species | 8 |
occasionally seen | 8 |
different forms | 8 |
nasal secretions | 8 |
common respiratory | 8 |
par les | 8 |
upper airways | 8 |
differential diagnoses | 8 |
normal experiments | 8 |
routinely recommended | 8 |
oil aspiration | 8 |
acute inflammatory | 8 |
uncomplicated cases | 8 |
using conventional | 8 |
may decrease | 8 |
toxic shock | 8 |
lung inflammation | 8 |
blood flow | 8 |
ventilatory support | 8 |
paragonimus spp | 8 |
severe viral | 8 |
internal medicine | 8 |
control group | 8 |
les techniques | 8 |
frequently encountered | 8 |
improve oxygenation | 8 |
hydrocortisone infusion | 8 |
hilar lymphadenopathy | 8 |
face mask | 8 |
orally administered | 8 |
viral hemorrhagic | 8 |
pneumonia diagnostics | 8 |
south african | 8 |
pandemic situation | 8 |
administration method | 8 |
also called | 8 |
also seen | 8 |
lactamase stable | 8 |
diagnostic utility | 8 |
lactam agent | 8 |
study design | 8 |
suspected cases | 8 |
oral anaerobes | 8 |
enhanced ct | 8 |
moderately severe | 8 |
measles pneumonia | 8 |
sample size | 8 |
patient group | 8 |
human transmission | 8 |
adenovirus serotype | 8 |
clinical judgment | 8 |
may contribute | 8 |
edematous fluid | 8 |
children will | 8 |
au moins | 8 |
antibiotic management | 8 |
now recognized | 8 |
connected layers | 8 |
among older | 8 |
admission criteria | 8 |
positive airway | 8 |
small airway | 8 |
respiratory bacterial | 8 |
probable pneumococcal | 8 |
clinically useful | 8 |
chapter respiratory | 8 |
pneumonia rates | 8 |
inhaled particles | 8 |
molecular detection | 8 |
preliminary randomized | 8 |
guide therapy | 8 |
aspirate samples | 8 |
radiologic pneumonia | 8 |
standard treatment | 8 |
assessment tool | 8 |
suppurative lung | 8 |
severe morbidity | 8 |
uenza virus | 8 |
positive pressure | 8 |
antibiotics prior | 8 |
pneumonia admitted | 8 |
tract complications | 8 |
suppurative bronchopneumonias | 8 |
clinical aspects | 8 |
pulmonary capillaries | 8 |
combination drug | 8 |
aureus infection | 8 |
using molecular | 8 |
antibiotic choice | 8 |
gestational age | 8 |
hospital referral | 8 |
microbiological methods | 8 |
cells may | 8 |
remains uncertain | 8 |
fl uids | 8 |
antigenic shift | 8 |
health protection | 8 |
ambulatory patients | 8 |
morphologic features | 8 |
generation cephems | 8 |
cause pulmonary | 8 |
nasopharyngeal swabs | 8 |
negative pneumonia | 8 |
specimens obtained | 8 |
immunocompromised child | 8 |
antibiotic utilization | 8 |
causes include | 8 |
onset vap | 8 |
hpiv infection | 8 |
mast cells | 8 |
language processing | 8 |
work dataset | 8 |
high resolution | 8 |
will focus | 8 |
pneumonia acquired | 8 |
commonly occurs | 8 |
fungus ball | 8 |
smoking history | 8 |
crazy paving | 8 |
death due | 8 |
common radiographic | 8 |
rate min | 8 |
viral rhinopneumonitis | 8 |
respiratory panel | 8 |
adaptive immunity | 8 |
considered significant | 8 |
antibiotic coverage | 8 |
nodular opacity | 8 |
decision making | 8 |
disease occurs | 8 |
care setting | 8 |
inflammatory responses | 8 |
clinical syndromes | 8 |
occurs mainly | 8 |
des explorations | 8 |
disease complex | 8 |
high index | 8 |
throat swabs | 8 |
alveolar cells | 8 |
often observed | 8 |
air pollution | 8 |
pneumonias caused | 8 |
poor prognosis | 8 |
pneumonia comparison | 8 |
pneumococcal carriage | 8 |
risk class | 8 |
acute bronchiolitis | 8 |
significant morbidity | 8 |
oral route | 8 |
shaking chills | 8 |
will develop | 8 |
integrated management | 8 |
comparator groups | 8 |
pneumococcal community | 8 |
ct may | 8 |
reticulonodular pattern | 8 |
du tractus | 8 |
polymorphonuclear leukocytes | 8 |
syncytial cells | 8 |
may play | 8 |
recent evidence | 8 |
latin america | 8 |
positive culture | 8 |
chinese medical | 8 |
intensive respiratory | 8 |
amplification tests | 8 |
routine diagnostic | 8 |
diffuse lung | 8 |
least days | 8 |
respiratory mucosa | 8 |
transthoracic lung | 8 |
pulmonary pathology | 8 |
may contain | 8 |
les points | 8 |
may remain | 8 |
influenza antiviral | 8 |
prevention strategies | 8 |
granulation tissue | 8 |
adenovirus infection | 8 |
points suivants | 8 |
well described | 8 |
large study | 8 |